REVISED LASER 510(k) GUIDANCE ELIMINATES MANUFACTURER TRAINING POLICY
This article was originally published in The Gray Sheet
Executive SummaryREVISED LASER 510(k) GUIDANCE ELIMINATES MANUFACTURER TRAINING POLICY statement that was in an earlier draft of the document. The language was deleted from the most recent draft of the "Guidance on the Content and Organization of a Premarket Notification for a Medical Laser" because FDA wants to address issues related to manufacturer-sponsored device training in a general forum, rather than on a device-by-device basis.
You may also be interested in...
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.